MLZ Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EDT
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)97.00
Market Cap
€18.70M
Enterprise Value€20.36
Total Cash (Recent Filing)€9.85M
Total Debt (Recent Filing)€421.00K
Price to Earnings (P/E)―
Beta-0.32
Next Earnings
Nov 16, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding427,177,150
10 Day Avg. Volume0
30 Day Avg. Volume97
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€24.38M
Bulls Say, Bears Say
Bulls Say
Operational RecoveryReturning to quarterly profit and delivering a second consecutive positive adjusted EBITDA quarter indicate that restructuring and operational improvements are gaining traction. If sustained, this recovery can strengthen internal funding capacity and support more disciplined growth over the next several quarters.
Balance Sheet StrengthSubstantial cash, negligible debt, and owned production assets provide financial flexibility while the business completes its turnaround. This reduces solvency pressure, gives management room to fund selected growth initiatives, and limits the need for balance-sheet repair over the medium term.
Pharmaceutical Platform ValidationPositive Phase II results in a randomized, controlled trial provide meaningful validation for MediPharm’s pharmaceutical formulation capabilities. The clinical evidence and provisional patents may strengthen the platform’s strategic value and support future product development beyond basic extract sales.
Bears Say
Unfinished Profitability TurnaroundDespite recent quarterly improvement, the trailing business remains unprofitable and is not yet self-funding. Negative operating and free cash flow can limit reinvestment capacity and increase reliance on liquidity management until stronger earnings consistently convert into cash.
Canadian Reimbursement PressureThe 30% VAC reimbursement reduction directly weakens economics in an established Canadian medical channel and has already coincided with lower quarterly revenue. Cost controls and mix changes may help, but reimbursement policy remains a durable risk to sales and margins.
German Competition And ScrutinyGermany is an important growth market, but stronger competition can pressure prices while increased regulatory scrutiny may complicate execution. These factors could make recent growth harder to sustain and limit the margin benefits expected from expanding international medical sales.
MediPharm Labs News
MLZ FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was €0.03 and its highest was €0.06 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is €18.70M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Nov 16, 2026 which is in 45 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on Aug 13, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.002 by €0.002.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 427,177,150 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of €0 in its last earnings report, beating expectations of -€0.002. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in DE:MLZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.
MLZ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial recovery: return to profitability, highest adjusted EBITDA since 2019, robust margin expansion, meaningful sequential revenue growth driven by international markets (notably Germany), successful Phase II LiBBY clinical results validating the pharmaceutical platform, and balance sheet strength. Headwinds include a material 30% VAC reimbursement cut that reduced Canadian medical revenue, ongoing pricing pressure and competition in key markets (Germany), and broader prescribing/reimbursement uncertainties. Overall, the positive operational execution, clinical validation, and improved profitability notably outweigh the identified challenges.View all DE:MLZ earnings summaries